Management strategies for the treatment of schizophrenia

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 12, 1999, Pages 13-17

  Kane, John M ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

COST OF ILLNESS; DISEASE DURATION; DOSE CALCULATION; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CLOZAPINE; DRUG ADMINISTRATION SCHEDULE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; PATIENT COMPLIANCE; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032982117     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-1416
2. McGurk SR. The effects of clozapine on cognitive functioning in schizophrenia. J Clin Psychiatry 1999;60(suppl 12):24-29
3. Cole JO, Goldberg SC, Davis JM. Drugs in the treatment of psychosis: controlled studies. In: Solomon T, ed. Psychiatric Drugs. New York, NY: Grune and Stratton; 1966:153-180
4. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993;29:309-314
5. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
6. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26
7. Prudo R, Blum HM. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia. Br J Psychiatry 1987;150:345-354
8. Hogarty GE, Ulrich RF, Mussare F, et al. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976;37:494-500
9. Johnson DA. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 1976;53:298-301
10. Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatr Scand Suppl 1980;279:64-76
11. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3-5 years: to stop or continue drugs? Br J Psychiatry 1981;138:490-494
12. Johnson DA. Long-term maintenance treatment in chronic schizophrenia: some observations on outcome and duration. Acta Psychiatr Belg 1981;81: 161-172
13. Wistedt B. A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 1981;64:65-84
14. McCreadie RG, Dingwall JM, Wiles DH, et al. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 1980;137:510-517
15. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148
16. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophreria: two-year results. Arch Gen Psychiatry 1991;48: 333-339
17. Jolley AG, Hirsch SR, Morrison E, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301:837-842
18. Pietzcker A, Gaebel W, Kopcke W, et al. Intermittent versus maintenance neuroleptic long term treatment in schizophrenia: 2 year results of a German multicenter study. J Psychiatr Res 1993;27:321-329
19. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 1997;54:453-463
20. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154: 1248-1254
21. Katie JM. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. J Clin Psychopharmacol 1986;6(suppl 1): 20S-23S
22. Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987;44:518-521
23. Johnson DA, Ludlow JM, Street K, et al. Double-blind comparison of half-dose and standard-Jose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 1987; 151:634-638
24. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. Arch Gen Psychiatry 1988;45:797-805
25. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302
26. Schooler NR, Severe JB, Glick ID, et al. Transition from acute to maintenance treatment prediction of stabilization. Int Clin Psychopharmacol 1996;11(suppl 2):85-91
27. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152:173-178
28. Pollack S, Woerner MG, Howard A, et al. Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull 1998;34:89-92
29. Essock SM, Hargreaves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospital: results from a randomized trial. Psychopharmacol Bull 1996;32:683-697
30. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(4, suppl):1-63
31. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
32. National Advisory Mental Health Council. Health care reform for Americans with severe mental illness: report of the National Advisory Mental Health Council. Am J Psychiatry 1993;150:1447-1465